Saved local watchlist · Deprioritization mentions · sorted by registry update date
Candidate queue
877 active trial–asset records · showing latest 25 · no composite ranking
An ingestion window is pending. Refresh resumes the next page.
| Asset / trial | Sponsor / phase | Status / stopping reason | Independent scores | Source |
|---|---|---|---|---|
| Delafloxacin PowderNCT06612255 | Melinta Therapeutics, Inc.PHASE1 | TERMINATED Study goals not met | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-09-11 |
| DelafloxacinNCT06612255 | Melinta Therapeutics, Inc.PHASE1 | TERMINATED Study goals not met | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-09-11 |
| IvabradineNCT03168529 | Phillip LevyPHASE4 | TERMINATED Lack of patient enrollment | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-09-11 |
| AbataceptNCT06680661 | Leland MethenyPHASE2 | SUSPENDED insufficient funding | ScienceUnknown SafetyUnknown Strategic-abandonment likelihood75 Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-09-10 |
| Mycophenolate MofetilNCT06680661 | Leland MethenyPHASE2 | SUSPENDED insufficient funding | ScienceUnknown SafetyUnknown Strategic-abandonment likelihood75 Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-09-10 |
| TacrolimusNCT06680661 | Leland MethenyPHASE2 | SUSPENDED insufficient funding | ScienceUnknown SafetyUnknown Strategic-abandonment likelihood75 Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-09-10 |
| Double Umbilical Cord TransplantNCT06680661 | Leland MethenyPHASE2 | SUSPENDED insufficient funding | ScienceUnknown SafetyUnknown Strategic-abandonment likelihood75 Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-09-10 |
| ThiotepaNCT06680661 | Leland MethenyPHASE2 | SUSPENDED insufficient funding | ScienceUnknown SafetyUnknown Strategic-abandonment likelihood75 Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-09-10 |
| FludarabineNCT06680661 | Leland MethenyPHASE2 | SUSPENDED insufficient funding | ScienceUnknown SafetyUnknown Strategic-abandonment likelihood75 Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-09-10 |
| CyclophosphamideNCT06680661 | Leland MethenyPHASE2 | SUSPENDED insufficient funding | ScienceUnknown SafetyUnknown Strategic-abandonment likelihood75 Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-09-10 |
| TalquetamabNCT06572605 | City of Hope Medical CenterPHASE1, PHASE2 | SUSPENDED pending amendment | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-09-10 |
| OsimertinibNCT06014827 | City of Hope Medical CenterPHASE2 | SUSPENDED Budget Issue | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-09-10 |
| SOC+BSB-2002NCT07566585 | BlueSphere Bio, IncPHASE1 | WITHDRAWN Company Decision | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potentialUnknown Operational complexityUnknown Licensing attractivenessUnknown | Registry evidence2026-09-10 |
| SOC+ BSB-2002NCT07566585 | BlueSphere Bio, IncPHASE1 | WITHDRAWN Company Decision | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potentialUnknown Operational complexityUnknown Licensing attractivenessUnknown | Registry evidence2026-09-10 |
| TPOXX 200Mg CapsuleNCT03972111 | SIGA TechnologiesPhase unknown | WITHDRAWN commitment fulfilled | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potentialUnknown Operational complexityUnknown Licensing attractivenessUnknown | Registry evidence2026-09-10 |
| nab-paclitaxelNCT04251533 | Novartis PharmaceuticalsPHASE3 | TERMINATED The study was terminated following a strategic decision to halt recruitment due to persistently slow enrollment. This decision was not driven by any new or unexpected safety concerns. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihood75 Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-09-10 |
| alpelisibNCT04251533 | Novartis PharmaceuticalsPHASE3 | TERMINATED The study was terminated following a strategic decision to halt recruitment due to persistently slow enrollment. This decision was not driven by any new or unexpected safety concerns. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihood75 Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-09-10 |
| JS111(AP-L1898 Capsules)NCT04993391 | Suzhou Junjing BioSciences Co., Ltd.PHASE1, PHASE2 | TERMINATED The study was stopped because of a change in the study strategy | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-09-10 |
| SOC+BSB-1001 Expansion DoseNCT06704152 | BlueSphere Bio, IncPHASE1, PHASE2 | TERMINATED Company Decision | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-09-10 |
| SOC + BSB-1001 Dose Escalation CohortNCT06704152 | BlueSphere Bio, IncPHASE1, PHASE2 | TERMINATED Company Decision | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-09-10 |
| ZiltivekimabNCT05636176 | Novo Nordisk A/SPHASE3 | TERMINATED No longer looking for participants. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential20 Operational complexity80 Licensing attractivenessUnknown | Registry evidence2026-09-10 |
| ALT-801NCT01029873 | Altor BioSciencePHASE1, PHASE2 | TERMINATED Sponsor decision | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-09-10 |
| CisplatinNCT01029873 | Altor BioSciencePHASE1, PHASE2 | TERMINATED Sponsor decision | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-09-10 |
| PembrolizumabNCT05665595 | Merck Sharp & Dohme LLCPHASE3 | TERMINATED Business Reason | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential20 Operational complexity80 Licensing attractivenessUnknown | Registry evidence2026-09-10 |
| Pembrolizumab/VibostolimabNCT05665595 | Merck Sharp & Dohme LLCPHASE3 | TERMINATED Business Reason | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential20 Operational complexity80 Licensing attractivenessUnknown | Registry evidence2026-09-10 |
Recent ingestion runs
| Source | Studies seen | Candidate writes | Status / finished |
|---|---|---|---|
| pubmed | 240 | 100 | finished2026-09-21T03:58:28.397783+00:00 |
| pubmed | 0 | 0 | failed2026-09-21T03:48:59.232056+00:00 |
| sec | 0 | 0 | finished2026-09-21T03:48:59.212906+00:00 |
| ClinicalTrials.gov | 300 | 258 | partial2026-09-21T03:48:59.189357+00:00 |
| ClinicalTrials.gov | 300 | 305 | Legacy run2026-09-21T03:45:47.341408+00:00 |
| ClinicalTrials.gov | 300 | 348 | Legacy run2026-09-21T03:38:48.082427+00:00 |